LifeTech Scientific Full Year 2023 Earnings: Misses Expectations

LifeTech Scientific (HKG:1302) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥1.27b (up 16% from FY 2022).
• Net income: CN¥263.2m (down 19% from FY 2022).
• Profit margin: 21% (down from 30% in FY 2022).
• EPS: CN¥0.06 (down from CN¥0.077 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

LifeTech Scientific Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 3.8%. Earnings per share (EPS) also missed analyst estimates by 26%.

Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Medical Equipment industry in Hong Kong.

Performance of the Hong Kong Medical Equipment industry.

The company's shares are down 4.8% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for LifeTech Scientific you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.